Articles On NeuroScientific Biopharmaceuticals (ASX:NSB)

NeuroScientific Biopharmaceuticals (ASX:NSB) has received feedback and guidance from the US FDA on its planned non-clinical and clinical development program of EmtinB as a treatment for adults with advanced glaucoma via a pre-IND me...

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Neuroscientific Biopharma to have a pre-IND meeting with US FDA The NSB stock price jumped as high as 30pc this morning Artrya signs first deal in Australia   NSB to have meeting with FDA NeuroScientific Biopharma (ASX:NSB) jumped as high...

The ASX200 finished off the first day of December down 0.2 of a percent – with all sectors, except energy, losing some ground.  In the Green Retail conglomerate Premier Investments (ASX:PMV) gained 2.8 per cent today following its Ann...

King Charles III loses coveted job of lurking on Australia’s $5 notes Adani down in the dumps after binning its multi-billion dollar cake sale Spacetalk heads for the moon on news the company’s found itself a new CEO   The ASX has had yet...

NeuroScientific Biopharmaceuticals (NSB) pockets a $3.7 million tax refund from the Australian Federal Government. The company received the government incentive payment for research and development undertaken during the 2021/2022 financi...

NSB files new patent in Australia Imugene doses first patient in Phase 1 trial Cronos and MGC Pharma give sales update   NSB announces patent filing in Australia NeuroScientific Biopharma (ASX:NSB) announced a new patent filing in Austral...

NeuroScientific Biopharmaceuticals (NSB) appoints Paul Rennie as interim CEO, nearly three months after former CEO Matt Liddelow resignedPaul Rennie is currently NSB’s Chair and will remain in both positions, but take more of an “active rol...

The ASX is poised to open higher on Wednesday after a rally in New York Oil prices higher as Saudi said OPEC+ wasn’t considering output increase Crypto broker Genesis near bankcruptcy The ASX is set to open higher on Wednesday after a bro...

NeuroScientific Biopharmaceuticals (NSB) CEO and Managing Director Matt Liddelow resigns from the company, effective immediatelyThe news comes just 48 hours after NSB’s announcement its phase one clinical trial for EmtinB was rejected by th...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Neuroscientific Biopharmaceuticals (NSB) astounds investors this morning with the news its phase one clinical trial for EmtinB has been rejectedThe company was informed by the Human Research Ethics Committee (HREC) of the rejection, citing...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

Neuroscientific Biopharma’s receipt of $1.13m in R&D tax incentive from the government is timely as it prepares for an early phase clinical trial of lead asset, EmtinB.  Australian drug development company Neuroscientific Biopharmaceuti...

Neuroscientific Biopharmaceuticals CEO and MD Matthew Liddelow says the company has entered one of the most exciting stages of its existence – successfully transitioning into clinical trials for its lead drug, peptide based compound, EmtinB...

Neuren’s Phase 2 clinical trial is now open for enrolment Neuroscientific submits an ethics approval request for Phase 1 trial Cannabis play Little Green Pharma signs $2m supply deal Neurological disorders specialist Neuren Pharmaceutical...

NeuroScientific Biopharmaceuticals (ASX:NSB) says it has submitted an application for Human Research Ethics Committee approval to commence a Phase I clinical trial of its lead drug candidate EmtinB.

NeuroScientific Biopharmaceuticals (NSB) recruits its first subject for an early-phase clinical trial The clinical stage drug development company announced the recruitment for its trial for lead drug candidate, EmtinB to treat neurodegener...

NeuroScientific Biopharmaceuticals (ASX:NSB) has announced the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB.

NeuroScientific Biopharmaceuticals (ASX:NSB) has announced positive preliminary results of lead drug candidate EmtinB in an animal model of Multiple sclerosis.

Highlights Investors are looking at clean energy stocks as the world is increasingly shifting from non-renewable to renewable energy sources. Australia intends to achieve a target of net-zero carbon emissions by 2050. The share prices...

Highlights NeuroScientific has received positive preliminary results from a study of its lead drug candidate EMTINB™ on multiple sclerosis. Mice treated with 10mg/kg and 20mg/kg doses of EmtinB™ constantly reached lower clinical scores...

ShareCafeLunch Report: 15 June, 2022 The Australian sharemarket has extended its fall for a fourth straight day with consumer staples and utilities advancing while the other sectors are in the red. Healthcare is the worst performer while th...

15 Jun 2022 - A snapshot of the stocks on the move featuring NeuroScientific Biopharmaceuticals (ASX:NSB), Lithium Plus Minerals (ASX:LPM) & Bluglass (ASX:BLG).

Neuroscientific announce positive results of EmtinB in mice model Island Pharma appoints new drug manufacturer for Phase 2 study Neuroscientific announces positive results for EmtinB NeuroScientific Biopharmaceuticals (ASX: NSB) has annou...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

NeuroScientific Biopharmaceuticals (NSB) reports “positive” preliminary results from an animal study for multiple sclerosis The study evaluated NSB’s lead drug candidate, EmtinB, across four dose groups in a mouse model, with the drug admi...

Highlights The HREC gave a green signal to NeuroScientific for conducting an early-phase clinical trial of its lead drug candidate. The trial will evaluate the biomarkers in human blood samples that provide proof for the working mechan...

Orthocell’s nerve reconstruction trial shows encouraging results Neuroscientific gets ethics approval to commence early-phase clinical trial Orthocell demonstrates encouraging trial results Orthocell (ASX:OCC) jumped 7% this morning after...

NeuroScientific Biopharmaceuticals (ASX:NSB) has submitted an application seeking approval for an early-phase clinical trial involving its lead drug candidate EmtinB.

IDX snaps up QLD-based radiology group for circa $38m  NSB starts HREC review process  Credit Suisse downgrades HLS, initiates coverage of ACL   Integral Diagnostics Limited (ASX:IDX) says it’s agreed to terms with Queensland-based Exact...

NeuroScientific Biopharmaceuticals (NSB) is on schedule to begin the clinical development of its lead drug candidate, EmtinB, in the first half of 2022 The company today has submitted an application for an early-phase clinical trial involv...

NeuroScientific Biopharmaceuticals (ASX:NSB) has reported positive outcomes from its preclinical safety and toxicology program involving its lead drug candidate EmtinB.

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

NeuroScientific Biopharmaceuticals (NSB) confirms the safety of its lead drug candidate, EmtinB The company has seen positive outcomes from its preclinical safety and toxicology program to support commencement of first in-human clinical tr...

Okay, who poked the S&P/ASX Emerging Companies index (XEC) this morning? Someone woke the sleeping Spinosaurus – the largest carnivorous dinosaur on this planet – that lies at the heart of our beloved small cap thermometer. It started r...

Oncosil’s medical device is being used commercially for the first time in Europe NeuroScientific Biopharma is set to commence Phase 1 clinical trial after a successful toxicology study Medical device company, OncoSil Medical (ASX:OSL), su...

NeuroScientific Biopharmaceuticals (NSB) completes an assessment of its lead drug candidate EmtinB for reducing inflammation in autoimmune diseases EmtinB significantly reduced inflammatory growth proteins, or cytokines, which are closely...

ASX to fall, US inflation highest in 40 years US inflation soared to 7.9% in the past year, outpacing the 7.5% year-on-year recorded last month as it hits a new 40-year high. The high CPI is expected to keep the Fed’s plan to hike rates, sl...

Neurotech International (NTI) appoints Alexandra Andrews as Chief Executive Officer (CEO), effective from Tuesday, next week Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation...

NeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an update on its lead drug candidate EmtinB. The company said it has executed on the successful completion of invitro genotoxicity and plasma prote...

NeuroScientific Biopharmaceuticals (NSB) completes two studies involving its lead drug candidate, EmtinB The completion of in-vitro genotoxicity and plasma protein binding studies comes in the lead up to the start of first-in-human Phase 1...

NeuroScientific Biopharmaceuticals (ASX:NSB) has reported outcomes from recently completed in vitro genotoxicity studies and plasma protein binding studies involving its lead drug candidate EmtinB.

ASX to open flat amid late sell off in US tech Wall Street mainly finished lower on Monday as a late selloff drove tech stocks down. In the last hour of trading, heavy selling volumes saw the Nasdaq falling by 0.58% as investors ditched big...

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price is rising today on the back of a clinical trial update. Shares in the company are trading at 34 cents at the time of writing, up 11.48%. Let’s take a look at what may be we...

The ASX 200 Health Index (XHJ) is trading higher by 0.70% at the time of writing, compared to the broader index which is up by 0.55%. OncoSil Medical (ASX:OSL) has released the final results of the PanCO clinical study for the treatment of...

NeuroScientific Biopharmaceuticals (NSB) reports positive results from off-target safety assessment of its lead drug candidate EmtinB EmtinB is a drug targeted at neurodegenerative conditions which affect the central nervous system such as...